Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay.
about
Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitolMetabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological settingEvaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetesHuman metabolic correlates of body mass indexMetabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions.The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoringA systems view of type 2 diabetes-associated metabolic perturbations in saliva, blood and urine at different timescales of glycaemic controlEpidemiology of Dysglycemia in Pregnant Oklahoma American Indian Women.Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy.Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes.Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes.1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus.Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients.Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assayDo glycemic marker levels vary by race? Differing results from a cross-sectional analysis of individuals with and without diagnosed diabetes.Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls.Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance.The clinical use of hemoglobin A1c.Pitfalls in hemoglobin A1c measurement: when results may be misleading.Control of postprandial glucose levels with insulin in type 2 diabetes.1,5-Anhydroglucitol in diabetes mellitus.A computational model of 1,5-AG dynamics during pregnancy.Metabolomics based markers predict type 2 diabetes in a 14-year follow-up study.The artificial pancreas: how sweet engineering will solve bitter problems.A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population.Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0.The metabolism and transport of 1,5-anhydroglucitol in cells.The use of 1.5-anhydroglucitol for monitoring glycemic control in islet transplant recipients.Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status.Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus.Time course metabolome of Roux-en-Y gastric bypass confirms correlation between leptin, body weight and the microbiome.The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysisEffect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol (坎格列净，一种钠-葡萄糖共转运体2抑制剂，对血清1,5-脱水葡萄糖醇测定的影响)
P2860
Q26801852-D9E94D01-8770-4B9A-A203-EB0821CDB016Q28748492-9BFFDFD3-8CFC-4FA0-B4A1-DC70561EA1F5Q33602114-5D3BD045-E411-489B-BE5E-390BC72C16C6Q34218551-426D4E37-BA3E-4561-AE79-C3191C34BA04Q34527732-7158FD79-FF94-4BA8-864B-6F7C5548A72BQ34726941-551DCC6D-5FCF-4182-8476-7193612AD5E4Q35349795-EBD171E6-A0EB-4ACA-9130-5ED9AD184FC7Q35842441-9BA49DEE-23F0-40B8-B03A-D2C5D2E8922DQ35916570-5725DD0B-EA6A-46B9-AB82-F58BF89028AFQ36194286-BA6F974A-6CF3-4164-91C4-315FB482DA08Q36392849-F4C7E218-959C-4E06-8325-0519871BDB73Q36437420-411ADF69-91D3-43EA-8A78-0241CF2933D1Q36488560-1C0791AA-BF87-47BC-A21F-39539B76C40CQ36660438-23830D0C-CBFC-4E94-9BFE-86B51158D5AEQ36807508-EB6E2091-81AB-404A-ADC0-F250BDC61E8FQ36911219-02DAEF28-A90A-4B2E-A52D-AE1EED9DDDD6Q37007055-99A6C465-AB96-4F38-8947-C61C0645A676Q37156757-248576DA-78C8-4189-BE2A-98FA74678654Q37292095-AA9DEBBB-7E98-48E2-83BA-67499F6518B9Q37404553-29FA9B12-120E-4A3E-BE2F-07128845EEC6Q37549703-5E48E2B3-1939-48CC-97DF-E814EACCB194Q37890790-FFF0DC92-EBB7-4AC3-A3CF-B1A2EC04A9F5Q38030840-7FC4712C-C5B3-4159-AD8D-01843AD81B98Q38618027-4E67E037-A669-4D26-80EA-29AB52A179E2Q38643179-519355A6-C3DA-4128-B39D-5A25B2118D1CQ40256085-2CF5E1FB-676E-4375-AADB-AB1F8610717EQ41020576-7AAABD50-814C-4E47-88BE-3C194DC93DB4Q41696859-3A814483-7A8F-4AED-A28C-9E804C20A783Q46740980-FF7FFB01-23E3-4F8C-AFF3-049AFD5191EFQ46960793-1D92B0D8-1990-4A59-B4ED-9E7E8870A36FQ48274733-3A6BF194-4B9E-4654-B605-46B62E80828AQ50876386-4327F971-EF4C-4186-9955-9283D51A3A43Q50916125-18B00EA4-3436-419F-B6AC-BC7E23CE1289Q51052616-8F8FF465-1A32-4674-95FF-3B629AEB8B9FQ51272348-5D32CC4F-E996-47B5-9A19-B4B57C21A98CQ51371829-1DBE61AF-4518-4CAB-A321-EEE4CE40968BQ55156251-FF3F8F7B-44DE-491F-A2AC-55BA72208805Q57412755-587E0AF8-ED06-44BB-997D-D9CAF1F877F8Q57479582-AC5A6D02-6D67-4BF8-8685-4F244F808930
P2860
Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@ast
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@en
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@nl
type
label
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@ast
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@en
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@nl
prefLabel
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@ast
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@en
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@nl
P2093
P1433
P1476
Circulating 1,5-anhydroglucito ...... trial of the GlycoMark assay.
@en
P2093
Erika B Ammirati
Janet B McGill
Mark J Sarno
Shannon Houghton
Theresa Gautille
Thomas G Cole
U.S. trial of the GlycoMark assay
William Nowatzke
P304
P356
10.2337/DIACARE.27.8.1859
P407
P577
2004-08-01T00:00:00Z